Ironwood Pharmaceuticals, Inc. repaid the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 at their scheduled maturity on June 15, 2026. The repayment was funded using available cash on hand, and no conversions were exercised by noteholders. Ironwood Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes specialty medicine products.
